BRAF and acral lentiginous melanoma: For instance, the frequency of BRAF and KIT mutations in ALM was only 15%–25.5% and 10%–20%, respectively.3, 6 Moreover, recent reports have shown that ALM was less susceptible to anti‐PD‐1 (programmed cell death‐1) therapy, in part because of lacking ligand expression of PD‐1, PD‐L1.3, 7, 8 Therefore, over half of ALM patients exclude from the benefits of BRAF‐, c‐Kit‐ and PD‐1‐targeted therapy.